Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

N6037

Sigma-Aldrich

Neridronate

≥97% (NMR), solid, bone resorption inhibitor

Synonyme(s) :

6-Amino-1-hydroxyhexylidene bisphosphonic acid, Neridronic acid, Nerixia

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C6H17NO7P2
Numéro CAS:
79778-41-9
Poids moléculaire :
277.15
Numéro MDL:
MFCD00866995
Code UNSPSC :
51111800
ID de substance PubChem :
24724553
Nomenclature NACRES :
NA.77

product name

Neridronate, ≥97% (NMR), solid

Description

may contain <1% (w/w) inorganic salts

Niveau de qualité

100

Pureté

≥97% (NMR)

Forme

solid

Couleur

white

Solubilité

H2O: >5 mg/mL

Température de stockage

2-8°C

Chaîne SMILES 

NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O

InChI

1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)

Clé InChI

PUUSSSIBPPTKTP-UHFFFAOYSA-N

Actions biochimiques/physiologiques

Neridronate is a bone resorption inhibitor. It is used to treat Osteogenesis Imperfecta, an "orphan disease" characterized by a fragility of the bone enough to be named the "illness of bones of crystal".

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Gloves

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 4

1 of 4

Etidronate disodium hydrate &#8805;97% (NMR), solid

Sigma-Aldrich

P5248

Etidronate disodium hydrate

Alendronate Sodium Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1599

Alendronate Sodium

Zoledronic acid monohydrate &#8805;98% (HPLC)

Sigma-Aldrich

SML0223

Zoledronic acid monohydrate

Zoledronic acid United States Pharmacopeia (USP) Reference Standard

USP

1724827

Zoledronic acid

Silvano Adami et al.
Calcified tissue international, 83(5), 301-307 (2008-10-24)
Compliance to osteoporosis treatment with oral bisphosphonates is very poor. Intermittent intravenous bisphosphonate is a useful alternative, but this route is not readily available. Neridronate, a nitrogen-containing bisphosphonate that can be given intramuscularly (IM), was tested in a phase 2
Patrizia D'Eufemia et al.
Pediatric research, 63(2), 203-206 (2007-12-20)
Prostaglandin E2 (PGE2) is an activator of bone remodeling, and increase levels of PGE2 are found in several disorders characterized by chronic inflammation. Bisphosphonates are used in the treatment of osteogenesis imperfecta (OI), an inherited disorder characterized by bone fragility
M Benucci et al.
Clinical and experimental rheumatology, 27(4), 567-573 (2009-09-24)
To assess the effects of intramuscular (im) neridronate (NE) on lumbar and femoral neck BMD and on markers of bone turnover in rheumatic patients under chronic low-dose glucocorticoids (GC) therapy. Sixty-nine osteopoenic and osteoporotic patients, affected by rheumatic diseases and
Pietro Persiani et al.
Medicine, 96(20), e6766-e6766 (2017-05-18)
The purpose of this study is to compare the results of 2 techniques, tension band wiring (TBW) and fixation with screws, in olecranon fractures in children affected with osteogenesis imperfecta (OI) type I. Between 2010 and 2014, 21 olecranon fractures
Massimo Varenna et al.
Rheumatology (Oxford, England), 52(3), 534-542 (2012-12-04)
Complex regional pain syndrome type I (CRPS-I) is a severely disabling pain syndrome for which no definite treatment has been established. The aim of this multi-centre, randomized, double-blind placebo-controlled trial was to test the efficacy of the amino-bisphosphonate neridronate in
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique